{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:18:59Z","timestamp":1773307139068,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,11]]},"DOI":"10.7759\/cureus.105041","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:58:01Z","timestamp":1773241081000},"source":"Crossref","is-referenced-by-count":0,"title":["Anti-tubercular Drugs Dominate Drug-Induced Liver Injury in Northern India: An Observational, Cross-Sectional Study of 100 Cases Using the Revised Electronic Causality Assessment Method (RECAM) and Drug-Induced Liver Injury Network (DILIN) Criteria"],"prefix":"10.7759","author":[{"given":"Fatima","family":"Rani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjan","family":"Awana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Patwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyog","family":"Sindhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarvesh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17040520","article-title":"The epidemiology of newly recognized causes of drug-induced liver injury: an update","volume":"17","author":"Bj\u00f6rnsson ES","year":"2024","unstructured":"Bj\u00f6rnsson ES. The epidemiology of newly recognized causes of drug-induced liver injury: an update. Pharmaceuticals (Basel). 2024, 17:10.3390\/ph17040520","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2019.11.006","article-title":"Alcohol and drug-induced liver injury: metabolism, mechanisms, pathogenesis and potential therapies(\u2606)","volume":"3","author":"Ding WX","year":"2019","unstructured":"Ding WX, Yang L. Alcohol and drug-induced liver injury: metabolism, mechanisms, pathogenesis and potential therapies(\u2606). Liver Res. 2019, 3:129-31. 10.1016\/j.livres.2019.11.006","journal-title":"Liver Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1750","article-title":"Idiosyncratic drug hepatotoxicity","volume":"4","author":"Kaplowitz N","year":"2005","unstructured":"Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005, 4:489-99. 10.1038\/nrd1750","journal-title":"Nat Rev Drug Discov"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/01926230590522356","article-title":"Recognizing drug-induced liver injury: current problems, possible solutions","volume":"33","author":"Lee WM","year":"2005","unstructured":"Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol. 2005, 33:155-64. 10.1080\/01926230590522356","journal-title":"Toxicol Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4425","article-title":"Association of NAT2 gene polymorphism with antitubercular drug-induced hepatotoxicity in the eastern Uttar Pradesh population","volume":"11","author":"Yadav D","year":"2019","unstructured":"Yadav D, Kumar R, Dixit RK, et al.. Association of NAT2 gene polymorphism with antitubercular drug-induced hepatotoxicity in the eastern Uttar Pradesh population. Cureus. 2019, 11:e4425. 10.7759\/cureus.4425","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.10.24","article-title":"Drug-induced liver injury: past, present and future","volume":"11","author":"Daly AK","year":"2010","unstructured":"Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics. 2010, 11:607-11. 10.2217\/pgs.10.24","journal-title":"Pharmacogenomics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2019.08.003","article-title":"Genetic predisposition to drug-induced liver injury","volume":"24","author":"Stephens C","year":"2020","unstructured":"Stephens C, Andrade RJ. Genetic predisposition to drug-induced liver injury. Clin Liver Dis. 2020, 24:11-23. 10.1016\/j.cld.2019.08.003","journal-title":"Clin Liver Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2020.108","article-title":"Ibuprofen increases the hepatotoxicity of ethanol through potentiating oxidative stress","volume":"29","author":"Kim M","year":"2021","unstructured":"Kim M, Lee EJ, Lim KM. Ibuprofen increases the hepatotoxicity of ethanol through potentiating oxidative stress. Biomol Ther (Seoul). 2021, 29:205-10. 10.4062\/biomolther.2020.108","journal-title":"Biomol Ther (Seoul)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0654-2","article-title":"Drug-induced liver injury: why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch?","volume":"41","author":"Danan G","year":"2018","unstructured":"Danan G, Teschke R. Drug-induced liver injury: why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch?. Drug Saf. 2018, 41:735-43. 10.1007\/s40264-018-0654-2","journal-title":"Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23577","article-title":"Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf Causality Assessment Method","volume":"51","author":"Rockey DC","year":"2010","unstructured":"Rockey DC, Seeff LB, Rochon J, et al.. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf Causality Assessment Method. Hepatology. 2010, 51:2117-26. 10.1002\/hep.23577","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2020.11.002","article-title":"The Indian network of drug-induced liver injury: etiology, clinical features, outcome and prognostic markers in 1288 patients","volume":"11","author":"Devarbhavi H","year":"2021","unstructured":"Devarbhavi H, Joseph T, Sunil Kumar N, et al.. The Indian network of drug-induced liver injury: etiology, clinical features, outcome and prognostic markers in 1288 patients. J Clin Exp Hepatol. 2021, 11:288-98. 10.1016\/j.jceh.2020.11.002","journal-title":"J Clin Exp Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10773-4","article-title":"Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia","volume":"19","author":"Choudhury A","year":"2025","unstructured":"Choudhury A, Kulkarni AV, Arora V, et al.. Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia. Hepatol Int. 2025, 19:1-69. 10.1007\/s12072-024-10773-4","journal-title":"Hepatol Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.101366","article-title":"Comparison of a novel score \"nod-ACLF\" to other established prognostic scores for prediction of mortality in APASL-ACLF patients: a cohort study from a tertiary care center of North India","volume":"14","author":"Patwa AK","year":"2024","unstructured":"Patwa AK, Yadav K, Atam V, et al.. Comparison of a novel score \"nod-ACLF\" to other established prognostic scores for prediction of mortality in APASL-ACLF patients: a cohort study from a tertiary care center of North India. J Clin Exp Hepatol. 2024, 14:101366. 10.1016\/j.jceh.2024.101366","journal-title":"J Clin Exp Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i13.1373","article-title":"Dissecting the molecular pathophysiology of drug-induced liver injury","volume":"24","author":"Ye H","year":"2018","unstructured":"Ye H, Nelson LJ, G\u00f3mez Del Moral M, Mart\u00ednez-Naves E, Cubero FJ. Dissecting the molecular pathophysiology of drug-induced liver injury. World J Gastroenterol. 2018, 24:1373-85. 10.3748\/wjg.v24.i13.1373","journal-title":"World J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29283","article-title":"Death and liver transplantation within 2 years of onset of drug-induced liver injury","volume":"66","author":"Hayashi PH","year":"2017","unstructured":"Hayashi PH, Rockey DC, Fontana RJ, et al.. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology. 2017, 66:1275-85. 10.1002\/hep.29283","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13223","article-title":"Liver safety assessment in clinical trials of new agents for chronic hepatitis B","volume":"27","author":"Fontana RJ","year":"2020","unstructured":"Fontana RJ, Avigan MI, Janssen HL, et al.. Liver safety assessment in clinical trials of new agents for chronic hepatitis B. J Viral Hepat. 2020, 27:96-109. 10.1111\/jvh.13223","journal-title":"J Viral Hepat"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09946-3","article-title":"Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update","volume":"13","author":"Sarin SK","year":"2019","unstructured":"Sarin SK, Choudhury A, Sharma MK, et al.. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019, 13:353-90. 10.1007\/s12072-019-09946-3","journal-title":"Hepatol Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3627","article-title":"Clinical characteristics of drug-induced liver injury and related risk factors","volume":"12","author":"Lu RJ","year":"2016","unstructured":"Lu RJ, Zhang Y, Tang FL, et al.. Clinical characteristics of drug-induced liver injury and related risk factors. Exp Ther Med. 2016, 12:2606-16. 10.3892\/etm.2016.3627","journal-title":"Exp Ther Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16083","article-title":"Methods for causality assessment of idiosyncratic drug-induced liver injury","volume":"45","author":"Garc\u00eda-Cort\u00e9s M","year":"2025","unstructured":"Garc\u00eda-Cort\u00e9s M, Matilla-Cabello G, Lucena MI. Methods for causality assessment of idiosyncratic drug-induced liver injury. Liver Int. 2025, 45:e16083. 10.1111\/liv.16083","journal-title":"Liver Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal GP","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, et al.. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011, 89:806-15. 10.1038\/clpt.2011.58","journal-title":"Clin Pharmacol Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932010-00005","article-title":"Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct","volume":"32","author":"Fontana RJ","year":"2009","unstructured":"Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009, 32:55-68. 10.2165\/00002018-200932010-00005","journal-title":"Drug Saf"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.5604\/01.3001.0009.8600","article-title":"Drug induced liver injury at a tertiary hospital in India: etiology, clinical features and predictors of mortality","volume":"16","author":"Rathi C","year":"2017","unstructured":"Rathi C, Pipaliya N, Patel R, Ingle M, Phadke A, Sawant P. Drug induced liver injury at a tertiary hospital in India: etiology, clinical features and predictors of mortality. Ann Hepatol. 2017, 16:442-50.","journal-title":"Ann Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2016.07.014","article-title":"Isoniazid metabolism and hepatotoxicity","volume":"6","author":"Wang P","year":"2016","unstructured":"Wang P, Pradhan K, Zhong XB, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 2016, 6:384-92. 10.1016\/j.apsb.2016.07.014","journal-title":"Acta Pharm Sin B"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4103\/ijmy.ijmy_15_21","article-title":"Predicting antitubercular drug-induced liver injury and its outcome and introducing a novel scoring system","volume":"10","author":"Raj Mani SS","year":"2021","unstructured":"Raj Mani SS, Iyyadurai R, Mishra AK, et al.. Predicting antitubercular drug-induced liver injury and its outcome and introducing a novel scoring system. Int J Mycobacteriol. 2021, 10:116-21. 10.4103\/ijmy.ijmy_15_21","journal-title":"Int J Mycobacteriol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2024.101771","article-title":"Histopathological changes in the human tissues in various types of poisoning: a cross-sectional autopsy study","volume":"13","author":"Kanani J","year":"2024","unstructured":"Kanani J, Sheikh MI, Jain S, Mesuriya S. Histopathological changes in the human tissues in various types of poisoning: a cross-sectional autopsy study. Toxicol Rep. 2024, 13:101771. 10.1016\/j.toxrep.2024.101771","journal-title":"Toxicol Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.12.041","article-title":"Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis","volume":"55","author":"Lucena MI","year":"2011","unstructured":"Lucena MI, Kaplowitz N, Hallal H, et al.. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol. 2011, 55:820-7. 10.1016\/j.jhep.2010.12.041","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani NP","year":"2021","unstructured":"Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021, 116:878-98. 10.14309\/ajg.0000000000001259","journal-title":"Am J Gastroenterol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8764093","article-title":"Metabolic comorbidities and risk of development and severity of drug-induced liver injury","volume":"2019","author":"Li X","year":"2019","unstructured":"Li X, Gao P, Niu J. Metabolic comorbidities and risk of development and severity of drug-induced liver injury. Biomed Res Int. 2019, 2019:8764093. 10.1155\/2019\/8764093","journal-title":"Biomed Res Int"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0286306","article-title":"Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?","volume":"18","author":"D Freire I","year":"2023","unstructured":"D Freire I, L Fielding K, AJ Moore D. Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?. PLoS One. 2023, 18:e0286306. 10.1371\/journal.pone.0286306","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00853","article-title":"Roussel Uclaf Causality Assessment Method for drug-induced liver injury: present and future","volume":"10","author":"Danan G","year":"2019","unstructured":"Danan G, Teschke R. Roussel Uclaf Causality Assessment Method for drug-induced liver injury: present and future. Front Pharmacol. 2019, 10:853. 10.3389\/fphar.2019.00853","journal-title":"Front Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/424261-anti-tubercular-drugs-dominate-drug-induced-liver-injury-in-northern-india-an-observational-cross-sectional-study-of-100-cases-using-the-revised-electronic-causality-assessment-method-recam-and-drug-induced-liver-injury-network-dilin-criteria","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:58:02Z","timestamp":1773241082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/424261-anti-tubercular-drugs-dominate-drug-induced-liver-injury-in-northern-india-an-observational-cross-sectional-study-of-100-cases-using-the-revised-electronic-causality-assessment-method-recam-and-drug-induced-liver-injury-network-dilin-criteria"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.105041","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,11]]}}}